Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy.

被引：0
|
作者：
Hawkins, Robert E.
Galvis, Victoria
Shanks, Jonathan
Dalal, Neha
Thistlethwaite, Fiona
Spencer-Shaw, Andrea
机构：
[1] Christie Canc Res UK, Manchester, Lancs, England
[2] Christie, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439
引用
收藏
页数：1
相关论文
共 50 条
  • [31] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY
    FYFE, G
    FISHER, RI
    ROSENBERG, SA
    SZNOL, M
    PARKINSON, DR
    LOUIE, AC
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 688 - 696
  • [32] HIGH-DOSE INTERLEUKIN-2 (HD IL2) ARMED WITH PATHOLOGY-BASED SELECTION CRITERIA: A REAL OPTION IN TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) AFTER TARGETED THERAPY
    Chow, S.
    Galvis, V.
    Evans, M.
    Chan, K.
    Spencer-Shaw, A.
    Leach, R.
    Keene, K.
    Shablak, A.
    Shanks, J.
    Thistlethwaite, F.
    Hawkins, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [33] Recurrent metastatic renal cell carcinoma presenting as a bleeding gastric ulcer after a complete response to high-dose interleukin-2 treatment
    Mascarenhas, B
    Konety, B
    Rubin, JT
    UROLOGY, 2001, 57 (01) : 168 - 168
  • [34] Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?
    Dillman, Robert O.
    Barth, Neil M.
    VanderMolen, Louis A.
    Mahdavi, Khosrow
    McClure, Stephanie E.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (06) : 337 - 343
  • [35] Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
    Gill, David M.
    Stenehjem, David D.
    Parikh, Kinjal
    Merriman, Joseph
    Sendilnathan, Arun
    Agarwal, Archana M.
    Hahn, Andrew W.
    Gupta, Sumati
    Tantravahi, Srinivas Kiran
    Samlowski, Wolfram E.
    Agarwal, Neeraj
    ECANCERMEDICALSCIENCE, 2016, 10
  • [36] High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis
    Brusky, JP
    Gailani, F
    Pathak, A
    Patel, H
    Aboseif, S
    BJU INTERNATIONAL, 2006, 97 (02) : 279 - 280
  • [37] High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: The University of Chicago experience
    Shulman, KL
    Stadler, WM
    Vogelzang, NJ
    UROLOGY, 1996, 47 (02) : 194 - 197
  • [38] SYMPTOMATIC EXACERBATION OF CROHN DISEASE AFTER TREATMENT WITH HIGH-DOSE INTERLEUKIN-2
    SPARANO, JA
    BRANDT, LJ
    DUTCHER, JP
    DUBOIS, JS
    ATKINS, MB
    ANNALS OF INTERNAL MEDICINE, 1993, 118 (08) : 617 - 618
  • [39] CHRONIC INFLAMMATORY ARTHRITIS AFTER TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 FOR MALIGNANCY
    MASSAROTTI, EM
    LIU, NY
    MIER, J
    ATKINS, MB
    AMERICAN JOURNAL OF MEDICINE, 1992, 92 (06): : 693 - 697
  • [40] The Role of High Dose Interleukin-2 in the Era of Targeted Therapy
    Gills, Jessie
    Parker, William P.
    Pate, Scott
    Niu, Sida
    Van Veldhuizen, Peter
    Mirza, Moben
    Holzbeierlein, Jeffery M.
    Lee, Eugene K.
    JOURNAL OF UROLOGY, 2017, 198 (03): : 538 - 545
12345